Erlotinib-induced bullous pemphigoid.
Luca
L
Stingeni
Leonardo
L
Bianchi
Vincenzo
V
Minotti
Paolo
P
Lisi
D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000556:secondary; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D017809:Fatal Outcome; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology; D008297:Male; D010391:Pemphigoid, Bullous / Q000139:chemically induced* / Q000473:pathology; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors